Zinc Oxide
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
- Zinc Oxide
- Pharmacist Assessment Report
- Zinc Oxide: Acne (disease)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Other Predicted Indications (For Reference)
- Disclaimer
Zinc Oxide: Acne (disease)
One-Sentence Summary
Zinc oxide is a topical skin protectant, originally used for conditions such as dermatitis, fungal skin infections (tinea), haemorrhoids and burns. The TxGNN model predicts it may be effective for acne (disease), but there are no registered clinical trials and only 3 indirect publications supporting this direction. This is a computational prediction at an early research stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, zinc oxide is a topical agent with established use as a skin protectant and soothing agent. It also has plausible anti-inflammatory, sebum-modulating and antibacterial activity, including against Cutibacterium acnes.
Acne is an inflammatory skin condition driven partly by bacterial colonisation. Zinc oxide’s existing uses in inflammatory and infective skin conditions (dermatitis, tinea, candidiasis) make a link to acne mechanistically conceivable.
The supporting literature is indirect, though. It consists of a general nanoparticle review, a preclinical microneedle study and a small split-face assessment whose relevance to zinc oxide cannot be confirmed. The very high TxGNN score is a computational output and does not replace clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21342155 | 2011 | Review | Int J Dermatol | Overview of engineered nanoparticles such as zinc oxide and titanium dioxide in skin care. Nano-preparations are under investigation for acne vulgaris and other skin conditions. |
| 36888703 | 2023 | Preclinical | Sci Adv | Ultrasound-responsive microneedle patch delivering zinc porphyrin-based nanoparticles for bacterial acne. Preclinical only, not zinc oxide itself. |
| 15536660 | 2004 | Small clinical study | Skin Res Technol | Split-face assessment in mild inflammatory catamenial acne. Design is unconfirmed and relevance to zinc oxide is unclear. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 598L | Not available | Not available | Not available |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
The knowledge graph also lists associations with several conditions, including hypertension, benign prostatic hyperplasia, sickle cell anaemia, primary hyperoxaluria, iron metabolism disorders (haemochromatosis, haemosiderosis), Wilson disease, coronary artery disease, heart conduction disease, hyperthyroidism and anxiety. These come from graph relationships, not label text, and should be verified against the PI before any interpretation. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is limited to indirect and preclinical sources, with no registered clinical trials. The high TxGNN score alone does not justify progression. The Australian listing also lacks the indication and product details needed for assessment.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank)
- The TGA-approved PI for warnings, contraindications and approved indications
- Product details for the Australian listing (name, dosage form, indication)
- Human clinical data on topical zinc oxide in acne, such as a controlled trial or systematic review
- Confirmation of the relevance of the split-face study (PMID 15536660) to zinc oxide
Other Predicted Indications (For Reference)
Nine further predictions were reviewed. Most have no supporting evidence and a weak mechanistic rationale, so none is recommended for progression at this time.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Anorectal stricture | 0.9946 | L5 | No evidence. Existing anorectal use does not address fibrotic stricture. |
| 3 | Anal polyp | 0.9931 | L5 | No evidence. No known mechanism against polyp pathology. |
| 4 | Papillary conjunctivitis | 0.9914 | L5 | No evidence. Ocular use raises unresolved safety and formulation concerns. |
| 5 | Postinfectious vasculitis | 0.9902 | L5 | No evidence. No established mechanism against immune-mediated vasculitis. |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.